MARIETTA, Ga., April 21, 2014 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today its sponsorship of Scott Rigsby, a double-amputee athlete. As part of the relationship, Rigsby will be taking his "inspire, inform, enable" message to Boston as he returns to run the 2014 Boston Marathon on April 21.
Rigsby was 18 when he lost his legs in a tragic truck accident. After a long journey that included surgeries, depression and uncertainty, Rigsby turned his life around reaching unprecedented heights as a world-class athlete. Rigsby became the first double-amputee to complete the world-famous Hawaiian Ironman Triathlon. Through his foundation, Rigsby provides education and support to wounded warriors returning from combat and other challenged individuals and athletes recovering from wounds or loss of limb.
"Scott's story of enabling and healing is very powerful and is in perfect sync with our mission," said Parker H. "Pete" Petit, Chairman and Chief Executive Officer at MiMedx. "Everything we do at MiMedx is driven by our commitment to improve wound healing through rapid regeneration of damaged tissue, whether trauma wounds or diabetic foot ulcers, and help restore normal daily function. We are very proud to sponsor Scott as he takes his inspirational message to Boston and continues his interaction with our wounded warriors."
Rigsby adds, "I am very excited about my new relationship with MiMedx. We share a deep desire to encourage people with hard-to-heal chronic wounds such as diabetic foot ulcers, or acute wounds from combat or trauma, like those suffered by victims of last year's bombing in Boston, to educate themselves about medical innovation so they can get back to living an active life as soon as possible. I tell this to returning soldiers, athletes, and others healing from wounds. I was inspired by others when I was down. Now, together with MiMedx, I can inspire others."
MiMedx® is an integrated developer, manufacturer and marketer of patent protected regenerative biomaterial products and bioimplants processed from human amniotic membrane. "Innovations in Regenerative Biomaterials" is the framework behind our mission to give physicians products and tissues to help the body heal itself. Our biomaterial platform technologies include AmnioFix® and EpiFix®, our tissue technologies processed from human amniotic membrane that is derived from donated placentas. Through our donor program, mothers delivering full-term Caesarean section births can elect in advance of delivery to donate the placenta in lieu of having it discarded as medical waste. We process the human amniotic membrane utilizing our proprietary PURION® process, to produce a safe and effective implant. MiMedx® is the leading supplier of amniotic tissue, having supplied over 225,000 allografts to date for application in the Wound Care, Surgical, Sports Medicine, Ophthalmic and Dental sectors of healthcare.
SOURCE MiMedx Group, Inc.